We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05408312
Recruitment Status : Active, not recruiting
First Posted : June 7, 2022
Last Update Posted : July 22, 2022
Lanzhou Institute of Biological Products Co., Ltd
Beijing Institute of Biological Products Co Ltd.
Information provided by (Responsible Party):
National Vaccine and Serum Institute, China

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : December 2023